Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Alexander E. Perl, Mark J. Levis, Andrew Wei, Hee-je Kim, June-won Cheong, Yu Zhang, Jian Li, Hisayuki Yokoyama, Naoko Hosono, Nahla Hasabou, Dina Elsouda, Jamie Jung-Hee An, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2024-204831

Published: 2024

Journal Articles

Streamline - Retrospective Cohort Study of FLT3- mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis

Amer M. Zeidan, Santosh Gautam, Rebekah Yu, Ziyu Lan, David L. Grinblatt, Dina ElSouda, James Spalding, Alana Block, Maelys Touya, Bhavik J. Pandya

Blood (2022) 140 (Supplement 1): 8124–8126.

https://doi.org/10.1182/blood-2022-166692

Published: 2022

Journal Articles

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Cristina Papayannidis, Blanca Boluda, Jonathan Canaani, Pascal Turlure, Ann De Becker, Anand Tandra, Dina Elsouda, Arnaud Houweling, Anil Upadhyay, Isabelle Wouters, Paresh Vyas

Blood (2022) 140 (Supplement 1): 11641–11643.

https://doi.org/10.1182/blood-2022-156296

Published: 2022

Journal Articles

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Amer M. Zeidan, MBBS, MHS, Adrienne M. Gilligan, PhD, Santosh Gautam, PhD, David L. Grinblatt, MD, Dina Elsouda, Loretta Sullivan, MD MPH, Bhavik J. Pandya, PharmD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136366

Published: 2020